Definitive treatment of primary vaginal cancer with radiotherapy

Multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09)

Ji Hyun Chang, Won Il Jang, Yongbae Kim, Jin Hee Kim, Young Seok Kim, Yeon Sil Kim, Won Park, Juree Kim, Won Sup Yoon, Joo Young Kim, Hak Jae Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective To assess the outcome of the treatment of primary vaginal cancer using definitive radiotherapy (RT) and to evaluate the prognostic factors of survival. Methods The medical records of nine institutions were retrospectively reviewed to find the patients with vaginal cancer treated with definitive RT with or without chemotherapy. A total of 138 patients met the inclusion criteria. None had undergone curative excision. Results The median follow-up time of the survivors was 77.6 months and the median survival time was 46.9 months. The 5-year overall survival, cancer-specific survival (CSS), and progression-free survival (PFS) rates were 68%, 80%, and 68.7%, respectively. In the survival analysis, the multivariate analysis showed that a lower the International Federation of Gynecology and Obstetrics (FIGO) stage and prior hysterectomy were favorable prognostic factors of CSS, and a lower FIGO stage and diagnosed prior to year 2000 were favorable prognostic factors of PFS. In the subgroup analysis of the patients with available human papillomavirus (HPV) results (n=27), no statistically significant relationship between the HPV status and recurrence or survival was found. Grade 3 or 4 acute and late toxicity were present in 16 and 9 patients, respectively. The FIGO stage and the tumor size were predictors of severe late toxicity. Conclusion The data clearly showed that a higher FIGO stage was correlated with a worse survival outcome and higher severe late toxicity. Therefore, precise RT and careful observation are crucial in advanced vaginal cancer. In this study, the HPV status was not related to the survival outcome, but its further investigation is needed.

Original languageEnglish
JournalJournal of Gynecologic Oncology
Volume27
Issue number2
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Vaginal Neoplasms
Radiation Oncology
Radiotherapy
Retrospective Studies
Survival
Gynecology
Obstetrics
Therapeutics
Disease-Free Survival
Neoplasms
Survival Analysis
Hysterectomy
Medical Records
Survivors
Multivariate Analysis
Survival Rate
Observation
Recurrence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Chang, Ji Hyun ; Jang, Won Il ; Kim, Yongbae ; Kim, Jin Hee ; Kim, Young Seok ; Kim, Yeon Sil ; Park, Won ; Kim, Juree ; Yoon, Won Sup ; Kim, Joo Young ; Kim, Hak Jae. / Definitive treatment of primary vaginal cancer with radiotherapy : Multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). In: Journal of Gynecologic Oncology. 2016 ; Vol. 27, No. 2.
@article{fc6d498065234ee0976886b4be6d248a,
title = "Definitive treatment of primary vaginal cancer with radiotherapy: Multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09)",
abstract = "Objective To assess the outcome of the treatment of primary vaginal cancer using definitive radiotherapy (RT) and to evaluate the prognostic factors of survival. Methods The medical records of nine institutions were retrospectively reviewed to find the patients with vaginal cancer treated with definitive RT with or without chemotherapy. A total of 138 patients met the inclusion criteria. None had undergone curative excision. Results The median follow-up time of the survivors was 77.6 months and the median survival time was 46.9 months. The 5-year overall survival, cancer-specific survival (CSS), and progression-free survival (PFS) rates were 68{\%}, 80{\%}, and 68.7{\%}, respectively. In the survival analysis, the multivariate analysis showed that a lower the International Federation of Gynecology and Obstetrics (FIGO) stage and prior hysterectomy were favorable prognostic factors of CSS, and a lower FIGO stage and diagnosed prior to year 2000 were favorable prognostic factors of PFS. In the subgroup analysis of the patients with available human papillomavirus (HPV) results (n=27), no statistically significant relationship between the HPV status and recurrence or survival was found. Grade 3 or 4 acute and late toxicity were present in 16 and 9 patients, respectively. The FIGO stage and the tumor size were predictors of severe late toxicity. Conclusion The data clearly showed that a higher FIGO stage was correlated with a worse survival outcome and higher severe late toxicity. Therefore, precise RT and careful observation are crucial in advanced vaginal cancer. In this study, the HPV status was not related to the survival outcome, but its further investigation is needed.",
author = "Chang, {Ji Hyun} and Jang, {Won Il} and Yongbae Kim and Kim, {Jin Hee} and Kim, {Young Seok} and Kim, {Yeon Sil} and Won Park and Juree Kim and Yoon, {Won Sup} and Kim, {Joo Young} and Kim, {Hak Jae}",
year = "2016",
month = "3",
day = "1",
doi = "10.3802/jgo.2016.27.e17",
language = "English",
volume = "27",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "2",

}

Definitive treatment of primary vaginal cancer with radiotherapy : Multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). / Chang, Ji Hyun; Jang, Won Il; Kim, Yongbae; Kim, Jin Hee; Kim, Young Seok; Kim, Yeon Sil; Park, Won; Kim, Juree; Yoon, Won Sup; Kim, Joo Young; Kim, Hak Jae.

In: Journal of Gynecologic Oncology, Vol. 27, No. 2, 01.03.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Definitive treatment of primary vaginal cancer with radiotherapy

T2 - Multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09)

AU - Chang, Ji Hyun

AU - Jang, Won Il

AU - Kim, Yongbae

AU - Kim, Jin Hee

AU - Kim, Young Seok

AU - Kim, Yeon Sil

AU - Park, Won

AU - Kim, Juree

AU - Yoon, Won Sup

AU - Kim, Joo Young

AU - Kim, Hak Jae

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Objective To assess the outcome of the treatment of primary vaginal cancer using definitive radiotherapy (RT) and to evaluate the prognostic factors of survival. Methods The medical records of nine institutions were retrospectively reviewed to find the patients with vaginal cancer treated with definitive RT with or without chemotherapy. A total of 138 patients met the inclusion criteria. None had undergone curative excision. Results The median follow-up time of the survivors was 77.6 months and the median survival time was 46.9 months. The 5-year overall survival, cancer-specific survival (CSS), and progression-free survival (PFS) rates were 68%, 80%, and 68.7%, respectively. In the survival analysis, the multivariate analysis showed that a lower the International Federation of Gynecology and Obstetrics (FIGO) stage and prior hysterectomy were favorable prognostic factors of CSS, and a lower FIGO stage and diagnosed prior to year 2000 were favorable prognostic factors of PFS. In the subgroup analysis of the patients with available human papillomavirus (HPV) results (n=27), no statistically significant relationship between the HPV status and recurrence or survival was found. Grade 3 or 4 acute and late toxicity were present in 16 and 9 patients, respectively. The FIGO stage and the tumor size were predictors of severe late toxicity. Conclusion The data clearly showed that a higher FIGO stage was correlated with a worse survival outcome and higher severe late toxicity. Therefore, precise RT and careful observation are crucial in advanced vaginal cancer. In this study, the HPV status was not related to the survival outcome, but its further investigation is needed.

AB - Objective To assess the outcome of the treatment of primary vaginal cancer using definitive radiotherapy (RT) and to evaluate the prognostic factors of survival. Methods The medical records of nine institutions were retrospectively reviewed to find the patients with vaginal cancer treated with definitive RT with or without chemotherapy. A total of 138 patients met the inclusion criteria. None had undergone curative excision. Results The median follow-up time of the survivors was 77.6 months and the median survival time was 46.9 months. The 5-year overall survival, cancer-specific survival (CSS), and progression-free survival (PFS) rates were 68%, 80%, and 68.7%, respectively. In the survival analysis, the multivariate analysis showed that a lower the International Federation of Gynecology and Obstetrics (FIGO) stage and prior hysterectomy were favorable prognostic factors of CSS, and a lower FIGO stage and diagnosed prior to year 2000 were favorable prognostic factors of PFS. In the subgroup analysis of the patients with available human papillomavirus (HPV) results (n=27), no statistically significant relationship between the HPV status and recurrence or survival was found. Grade 3 or 4 acute and late toxicity were present in 16 and 9 patients, respectively. The FIGO stage and the tumor size were predictors of severe late toxicity. Conclusion The data clearly showed that a higher FIGO stage was correlated with a worse survival outcome and higher severe late toxicity. Therefore, precise RT and careful observation are crucial in advanced vaginal cancer. In this study, the HPV status was not related to the survival outcome, but its further investigation is needed.

UR - http://www.scopus.com/inward/record.url?scp=84955125343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955125343&partnerID=8YFLogxK

U2 - 10.3802/jgo.2016.27.e17

DO - 10.3802/jgo.2016.27.e17

M3 - Article

VL - 27

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 2

ER -